PCA
TGTX icon

Providence Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Providence Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-127
Closed -$2.26K – 374
2024
Q2 		$2.26K Hold
127
– – ﹤0.01% 306
2024
Q1 		$1.93K Hold
127
– – ﹤0.01% 298
2023
Q4 		$2.17K Hold
127
– – ﹤0.01% 301
2023
Q3 		$1.06K Hold
127
– – ﹤0.01% 326
2023
Q2 		$3.15K Hold
127
– – ﹤0.01% 260
2023
Q1 		$1.91K Hold
127
– – ﹤0.01% 274
2022
Q4 		$1.5K Buy
+127
New +$922 ﹤0.01% 257

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Providence Capital Advisors's TGTX Position: Q3 2024 in Review

Providence Capital Advisors sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 127 shares — an estimated $2.26K sold.

Providence Capital Advisors first reported a position in TGTX in Q4 2022 and held it in 7 quarters. The position peaked at $3.15K in Q2 2023. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Providence Capital Advisors reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Providence Capital Advisors sold 127 TG Therapeutics shares in Q3 2024, an estimated $2.26K.
  • Providence Capital Advisors first reported a position in TG Therapeutics in Q4 2022 and held it in 7 quarters.
  • Providence Capital Advisors's TG Therapeutics position peaked at $3.15K in Q2 2023.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Providence Capital Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.